Top 5 Most Influential Psychedelic Studies
We unpack five of the most important psychedelic studies conducted in recent years as psychedelics become mainstream medicine.
Author: James Hallifax
My Favorite Psychedelic Stocks: Part 1
Our resident Psychedelic Investor details five companies he thinks are in strong position to win the psychedelic medicine race.
Oklahoma House Passes Psilocybin Decriminalization Bill
Now it’s up to the state’s Senate to consider the bill decriminalizing the possession of psilocybin and authorizing research.
Study Finds Psilocybin Anti-Depression Effects Last at Least One Year
A year after a Johns Hopkins psilocybin-assisted therapy study, researchers find the number of people who benefited from receiving two doses actually increased.
How Long Until Psychedelic Stocks Payoff?
Our resident Psychedelic Investor explores one of the biggest questions on minds of those investing in psychedelic stocks.
Cathie Woods’ ARK Invest Conducting ‘Deep Dive’ Into Psychedelic Stocks
Cathie Wood and Ark Invest buying psychedelic stocks will be significant for the industry, as Wood holds a megaphone with which she communicates to retail growth investors.
Cathie Wood’s ARK Genomic Revolution ETF Buys Psychedelic Stock
Our resident Psychedelic Investor explains why this is an important moment for the psychedelics sector.
DMT Vape Pen Patent Illustrates a Big Problem in the Psychedelics Industry
Problematic patents have serious implications for the entire psychedelics industry.
The Thesis for Investing in Psychedelic Stocks
Our resident Psychedelic Investor makes the case why the psychedelic sector may yield big returns.
4 Tips for Investing in Psychedelic Stocks During a Market Downturn
Friendly advice for responsibly managing speculative bets on psychedelic stocks that may rise like a phoenix or burn to the ground.
End of content
End of content